ArticleBMC cardiovascular disorders2026
Effects of cardiac resynchronization therapy in adults with congenital heart disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCardiac resynchronization therapy (CRT) is well-established in acquired heart failure, but evidence in adults with congenital heart disease (ACHD) remains limited. Current guidelines, extrapolated from non-congenital populations, may not fully address the anatomical and electrophysiological complexities in ACHD. This study aimed to evaluate the safety and efficacy of CRT in ACHD, focusing on changes in QRS duration, systemic ventricular function (SVF), and New York Heart Association (NYHA) class.
methodsA retrospective multicenter cohort study was conducted across two tertiary ACHD centers. ACHD patients who underwent CRT implantation between 2014 and 2024 were included. Primary outcomes were QRS duration, SVF, and NYHA class at 3, 6, and 12 months post-implantation, and peri-procedural clinical and device-related outcomes were assessed. Mixed models were used to analyze longitudinal changes, adjusting for de novo vs. upgrade CRT implantation, left bundle branch block (LBBB) vs. non-LBBB QRS morphology, and systemic left vs. right ventricle (sRV) anatomy.
results101 patients were included. The mean age was 53 ± 14 year, 41 (40.6%) were female and 48 (47.5%) underwent an upgrade procedure to CRT. Twenty-two patients (21.8%) had mild, 57 (56.4%) moderate, and 22 (21.8%) severe congenital heart disease, and 16 (15.8%) had a sRV. Six patients (5.9%) experienced a procedure-related complication requiring revision (6.6 per 100 patient-years follow-up), and one patient (1.0%) died from end-stage heart failure in the year after CRT implantation. CRT was associated with significant improvements in QRS duration, SVF, and NYHA class at 3, 6, and 12 months (p < 0.05 for all). QRS reduction was more pronounced after upgrade procedures. Improvements in QRS, SVF, and NYHA class extended to patients with a sRV and with non-LBBB QRS morphology. At one year follow-up, 68 patients (72.3%) showed improvement of at least 1 class of NYHA and/or SVF.
conclusionsThis study supports CRT as a safe and effective therapy in ACHD patients, including those with sRV or non-LBBB QRS morphology, emphasizing the need for individualized decision-making beyond standard guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.